Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD131
MIFTS: 59

Bladder Urothelial Carcinoma

Categories: Cancer diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bladder Urothelial Carcinoma

About this section

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 12 15
Transitional Cell Carcinoma of the Bladder 29 6
Transitional Cell Carcinoma of Bladder 12 70
Bladder Transitional Cell Carcinoma 12 17
Urinary Bladder Urothelial Carcinoma 12
Carcinoma Transitional Cell Bladder 54
Urothelial Bladder Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4006
NCIt 50 C39851
SNOMED-CT 67 393562002
UMLS 70 C0279680
Sources

Summaries for Bladder Urothelial Carcinoma

About this section
Disease Ontology : 12 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary : Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of the bladder, is related to squamous cell papilloma and in situ carcinoma. An important gene associated with Bladder Urothelial Carcinoma is TUG1 (Taurine Up-Regulated 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Amphotericin B and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include lining of the bladder, breast and prostate, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Bladder Urothelial Carcinoma

About this section

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 566)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 31.1 TP53 HRAS CDKN2A
2 in situ carcinoma 30.8 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
3 thyroid cancer, nonmedullary, 1 30.8 PVT1 MEG3 MALAT1 HOTAIR
4 transitional cell carcinoma 30.8 U2AF1 TP53 PTEN HRAS FGFR3 ERBB2
5 villous adenoma 30.7 TP53 KRAS HRAS
6 papilloma 30.7 TP53 PTEN KRAS FGFR3 ERBB2 CDKN2A
7 adenoma 30.6 TP53 PIK3CA KRAS CTNNB1 CDKN2A AKT1
8 bladder cancer 30.6 TUG1 TP53 PVT1 PTEN PIK3CA MEG3
9 tuberous sclerosis 1 30.6 PTEN MTOR AKT1
10 thyroid carcinoma 30.6 PVT1 PTEN PIK3CA MALAT1 HOTAIR GAS5
11 exanthem 30.6 MTOR KRAS HRAS ERBB2 AKT1
12 thymoma 30.5 TP53 MTOR HRAS AKT1
13 appendix adenocarcinoma 30.5 KRAS HRAS
14 nevus, epidermal 30.5 PTEN PIK3CA KRAS HRAS FGFR3 AKT1
15 mucinous adenocarcinoma 30.5 TP53 KRAS ERBB2 CDKN2A
16 plasmacytoma 30.5 PVT1 CTNNB1 CDKN2A AKT1
17 tuberous sclerosis 30.5 TP53 PTEN PIK3CA MTOR AKT1
18 large cell carcinoma 30.4 MTOR KRAS HRAS ERBB2
19 vulva cancer 30.4 TP53 PTEN PIK3CA HRAS ERBB2 CDKN2A
20 intrahepatic cholangiocarcinoma 30.4 TUG1 TP53 KRAS IDH1 ERBB2 CTNNB1
21 signet ring cell adenocarcinoma 30.3 TP53 KRAS HRAS ERBB2 CTNNB1
22 small cell carcinoma 30.3 TP53 PTEN KRAS ERBB2 CDKN2A
23 lynch syndrome 30.1 TP53 PTEN PIK3CA KRAS HRAS FGFR3
24 carcinosarcoma 30.1 TP53 PTEN PIK3CA KRAS HRAS ERBB2
25 retinoblastoma 30.1 TP53 MEG3 MALAT1 HOTAIR CDKN2A
26 peripheral nervous system disease 30.1 U2AF1 TP53 PTEN MTOR HRAS ERBB2
27 cholangiocarcinoma 30.0 TUG1 TP53 PIK3CA MTOR MALAT1 KRAS
28 renal cell carcinoma, papillary, 1 30.0 TP53 PTEN PIK3CA MTOR HRAS FGFR3
29 li-fraumeni syndrome 30.0 TP53 PTEN KRAS IDH1 HRAS ERBB2
30 colorectal adenocarcinoma 30.0 TP53 PTEN KRAS HRAS ERBB2 CTNNB1
31 renal cell carcinoma, nonpapillary 30.0 TUG1 TP53 PVT1 PTEN PIK3CA MTOR
32 skin carcinoma 29.9 TP53 PTEN PIK3CA MTOR KRAS HRAS
33 pancreatic adenocarcinoma 29.9 U2AF1 TP53 PIK3CA KRAS HRAS ERBB2
34 suppression of tumorigenicity 12 29.9 U2AF1 TP53 PTEN PIK3CA IDH1 HRAS
35 adenocarcinoma 29.9 TP53 PTEN PIK3CA MALAT1 KRAS HRAS
36 gastric adenocarcinoma 29.6 TP53 PTEN PIK3CA MTOR KRAS HRAS
37 skin melanoma 29.6 U2AF1 TP53 PTEN PIK3CA MTOR KRAS
38 melanoma 29.3 TP53 PVT1 PTEN PIK3CA MTOR MEG3
39 cervical cancer 29.1 U2AF1 TUG1 TP53 PVT1 PTEN PIK3CA
40 prostate cancer 29.1 TUG1 TP53 PVT1 PTEN PIK3CA MTOR
41 breast cancer 29.0 TUG1 TP53 PVT1 PTEN PIK3CA MTOR
42 hepatocellular carcinoma 29.0 TUG1 TP53 PVT1 PTEN PIK3CA MTOR
43 colorectal cancer 28.8 U2AF1 TUG1 TP53 PVT1 PTEN PIK3CA
44 infiltrating bladder urothelial carcinoma sarcomatoid variant 11.6
45 non-invasive bladder urothelial carcinoma 11.5
46 non-papillary transitional cell carcinoma of the bladder 11.5
47 invasive bladder transitional cell carcinoma 11.5
48 bladder small cell carcinoma 11.4
49 clear cell variant infiltrating bladder urothelial carcinoma 11.4
50 micropapillary variant infiltrating bladder urothelial carcinoma 11.4

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma
Sources

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

About this section

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

26 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.77 HRAS KRAS PIK3CA MTOR
2 Decreased viability GR00055-A-2 10.77 HRAS KRAS PIK3CA MTOR
3 Decreased viability GR00055-A-3 10.77 KRAS
4 Decreased viability GR00106-A-0 10.77 KRAS
5 Decreased viability GR00221-A-1 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA CDKN2A
6 Decreased viability GR00221-A-2 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.77 AKT1 FGFR3 HRAS CDKN2A ERBB2
8 Decreased viability GR00221-A-4 10.77 AKT1 PIK3CA CDKN2A ERBB2 MTOR
9 Decreased viability GR00249-S 10.77 AKT1 FGFR3
10 Decreased viability GR00301-A 10.77 KRAS
11 Decreased viability GR00342-S-1 10.77 MTOR
12 Decreased viability GR00342-S-2 10.77 MTOR
13 Decreased viability GR00381-A-1 10.77 KRAS
14 Decreased viability GR00402-S-2 10.77 PIK3CA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.22 MTOR
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.22 PIK3CA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.22 ERBB2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.22 PIK3CA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.22 AKT1 MTOR PIK3CA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.22 ERBB2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.22 PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.22 MTOR
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.22 AKT1 PIK3CA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.22 PIK3CA
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.22 PIK3CA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.22 AKT1 MTOR PIK3CA
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.22 PIK3CA
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.22 AKT1
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.22 MTOR PIK3CA
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.22 MTOR
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.22 AKT1
32 Decreased cell migration GR00055-A-1 9.86 AKT1 FGFR3
33 Decreased cell migration GR00055-A-3 9.86 HRAS MTOR PIK3CA
34 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.32 CTNNB1

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.13 AKT1 CDKN2A CTNNB1 ERBB2 HRAS KRAS
2 embryo MP:0005380 10.11 AKT1 CDKN2A CTNNB1 ERBB2 KRAS MTOR
3 integument MP:0010771 10.1 AKT1 CDKN2A CTNNB1 ERBB2 FGFR3 HRAS
4 digestive/alimentary MP:0005381 10.08 CDKN2A CTNNB1 ERBB2 FGFR3 HRAS KRAS
5 muscle MP:0005369 10.07 AKT1 CDKN2A CTNNB1 ERBB2 HRAS KRAS
6 neoplasm MP:0002006 10.02 AKT1 CDKN2A CTNNB1 ERBB2 FGFR3 HRAS
7 no phenotypic analysis MP:0003012 9.86 CDKN2A CTNNB1 FGFR3 HRAS KRAS MTOR
8 normal MP:0002873 9.81 AKT1 CTNNB1 ERBB2 FGFR3 HRAS KRAS
9 respiratory system MP:0005388 9.7 AKT1 CDKN2A CTNNB1 ERBB2 FGFR3 HRAS
10 skeleton MP:0005390 9.4 AKT1 CDKN2A CTNNB1 ERBB2 FGFR3 HRAS
Sources

Drugs & Therapeutics for Bladder Urothelial Carcinoma

About this section

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
2
Tocopherol Approved, Investigational Phase 3 1406-66-2
3
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
4
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
5
Eflornithine Approved, Withdrawn Phase 3 70052-12-9 3009
6
Aminolevulinic acid Approved Phase 3 106-60-5 137
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
9
nivolumab Approved Phase 3 946414-94-4
10
Durvalumab Approved, Investigational Phase 3 1428935-60-7
11
BCG vaccine Approved, Investigational Phase 3
12
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
13
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
14
Vinblastine Approved Phase 3 865-21-4 13342 241903
15
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
16
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
17
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
18
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
19
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
20
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
21
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23 Tocotrienol Investigational Phase 3 6829-55-6
24
Fenretinide Investigational Phase 3 65646-68-6
25
Levulinic acid Experimental Phase 3 123-76-2 11579
26 Liposomal amphotericin B Phase 2, Phase 3
27 Tocotrienols Phase 3
28 Tocopherols Phase 3
29 Antioxidants Phase 3
30 Vitamins Phase 3
31 Protective Agents Phase 3
32 Lipid Regulating Agents Phase 3
33 Vasodilator Agents Phase 3
34 Vitamin B3 Phase 3
35 Nicotinic Acids Phase 3
36 Hypolipidemic Agents Phase 3
37 Antiparasitic Agents Phase 3
38 Antiprotozoal Agents Phase 3
39 Photosensitizing Agents Phase 3
40 Halichondrin B Phase 3
41 Immunologic Factors Phase 3
42 Vaccines Phase 3
43 Pharmaceutical Solutions Phase 3
44 Protein Kinase Inhibitors Phase 3
45 Anti-Bacterial Agents Phase 3
46 Antibiotics, Antitubercular Phase 3
47 Mitomycins Phase 3
48 Adjuvants, Immunologic Phase 3
49 Vitamin B9 Phase 3
50 Folate Phase 3

Interventional clinical trials:

(show top 50) (show all 164)
# Name Status NCT ID Phase Drugs
1 A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
2 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT] Unknown status NCT00553345 Phase 3 selenium;vitamin E
3 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) Unknown status NCT00553124 Phase 3 selenium;vitamin E
4 Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors Unknown status NCT00003725 Phase 3 valrubicin
5 Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
6 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
7 Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study Completed NCT00867347 Phase 3
8 Phase III Randomized Chemoprevention Study of Selenium on the Recurrence of Non-invasive Bladder Cancer Completed NCT00729287 Phase 3
9 A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer Completed NCT00033436 Phase 3 carbogen
10 2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
11 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
12 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
13 Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
14 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
15 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
16 A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
17 Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
18 A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
19 A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER Completed NCT00002490 Phase 3 mitomycin C
20 Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
21 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
22 Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder Completed NCT00003623 Phase 3
23 A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder Completed NCT00330499 Phase 3 Cisplatin
24 Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial Recruiting NCT04637594 Phase 3 Pembrolizumab;Nivolumab;Atezolizumab;Durvalumab;Avelumab
25 A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy Recruiting NCT04579224 Phase 3 Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel
26 S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer Active, not recruiting NCT03091660 Phase 3
27 A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00352079 Phase 3 gefitinib
28 The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder Terminated NCT00003824 Phase 3 cephalexin;Ciprofloxacin
29 Chemoresection With 4 Weekly Intravesical Instillations Of Mitomycin C Versus Transurethral Resection (TUR) Followed By One Single Immediate Instillation Of Mitomycin C In Single, Small, Papillary Stage Ta, T1 Bladder Tumors: A Prospective Randomized Phase III Trial Terminated NCT00042887 Phase 3 mitomycin C
30 MVAC (Methotrexate, Vinblastine, Adriamycin, and Cisplatin) in Organ-Confined Bladder Cancer Based on p53 Status Terminated NCT00005047 Phase 3 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine
31 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
32 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
33 A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder Unknown status NCT01222676 Phase 2 cisplatin;gemcitabine hydrochloride;sorafenib tosylate
34 A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy Unknown status NCT01118039 Phase 2 sunitinib malate
35 Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer. Unknown status NCT01196403 Phase 2
36 Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
37 First Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma of the Bladder With a Combination of Cisplatin-Paclitaxel-Gemcitabine Unknown status NCT00006118 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
38 Biomarker Discovery Study to Identify Patients With Advanced Urothelial Cancer Benefitting From Pembrolizumab Treatment Unknown status NCT03263039 Phase 2 Pembrolizumab
39 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
40 Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta (TGFβ) Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer (UC) Failing First-line Treatment. Unknown status NCT01620970 Phase 2 PF03446962
41 An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer. Unknown status NCT02736266 Phase 2 Pembrolizumab (MK-3475)
42 A Single-center Randomized Controlled Trial of Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma Treated With First-line Gemcitabine Plus Cisplatin Unknown status NCT03389438 Phase 2
43 A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder Completed NCT00047216 Phase 2 tipifarnib
44 A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Superficial Bladder Cancer Completed NCT01687244 Phase 2 INSTILADRIN
45 Phase 1-2 Study of the Association of Gemzar ® - Cisplatin-concurrent Radiotherapy in Patients With Non-metastatic Tumors of the Bladder Completed NCT00556621 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
46 Phase II Single Arm, Open Label, Single Institution Study of Neoadjuvant Sunitinib (SUTENT) in Patients With Muscle-Invasive Locally Advanced Transitional Cell Carcinoma of the Bladder Completed NCT00526656 Phase 2 sunitinib malate
47 A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
48 A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
49 A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin Completed NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
50 A Multicentre Phase II Trial to Determine the Efficacy of the Anti-Tyrosine Kinase Sunitinib (Sutent®) as Second Line Therapy in Patients With Transitional Cell Carcinoma (TCC) of the Urothelium Which Failed or Progressed After First Line Chemotherapy for Advanced or Metastatic Disease Completed NCT00792025 Phase 2 sunitinib malate

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Sources

Genetic Tests for Bladder Urothelial Carcinoma

About this section

Genetic tests related to Bladder Urothelial Carcinoma:

# Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 29
Sources

Anatomical Context for Bladder Urothelial Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Urothelial Carcinoma:

19
Lining Of The Bladder

MalaCards organs/tissues related to Bladder Urothelial Carcinoma:

40
Breast, Prostate, Lung, Lymph Node, Thyroid, Skin, Liver
Sources

Publications for Bladder Urothelial Carcinoma

About this section

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 2787)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
2
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. 6
24625776 2014
3
Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. 61 54
17311305 2007
4
Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. 54 61
17293658 2007
5
Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. 54 61
15733109 2005
6
[Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67]. 61 54
12731328 2003
7
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. 54 61
11696726 2001
8
Expression of pS2 protein and its relation with the Ki-67 proliferative indices and tumor recurrence in superficial bladder carcinomas. 54 61
11528193 2001
9
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. 61 54
11342899 2001
10
The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. 54 61
10687971 2000
11
Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. 54 61
10699635 2000
12
p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. 61 54
9187909 1997
13
[Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. 54 61
9275651 1996
14
Expression of p53 product in Chinese human bladder carcinoma. 54 61
7688167 1993
15
The prognostic value and potential subtypes of immune activity scores in three major urological cancers. 61
32853461 2021
16
Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). 61
33472913 2021
17
Cell-Intrinsic Tumorigenic Functions of PPARγ in Bladder Urothelial Carcinoma. 61
33431608 2021
18
Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma. 61
33762601 2021
19
Methodology for triage of urologic surgical cases in the setting of a pandemic. 61
33676485 2021
20
The metabolic syndrome is associated with the risk of urothelial carcinoma from a health examination database. 61
33231793 2021
21
Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy. 61
33665361 2021
22
Correlation between immunohistochemical expression of Ki-67and P63 and aggressiveness of urinary bladder urothelial carcinoma. 61
33206579 2021
23
Weighted gene co-expression network analysis can sort cancer-associated fibroblast-specific markers promoting bladder cancer progression. 61
32657439 2021
24
Competing endogenous RNA network analysis reveals pivotal ceRNAs in bladder urothelial carcinoma. 61
33718081 2021
25
Correlations between glycolysis with clinical traits and immune function in bladder urothelial carcinoma. 61
33558879 2021
26
Identification and Complete Validation of Prognostic Gene Signatures for Human Papillomavirus-Associated Cancers: Integrated Approach Covering Different Anatomical Locations. 61
33361419 2021
27
Identification of a ten-long noncoding RNA signature for predicting the survival and immune status of patients with bladder urothelial carcinoma based on the GEO database: a superior machine learning model. 61
33621953 2021
28
Rs-1884444 G/T variant in IL-23 receptor is likely to modify risk of bladder urothelial carcinoma by regulating IL-23/IL-17 inflammatory pathway. 61
33187815 2021
29
Inference of gene regulatory networks using pseudo-time series data. 61
33576787 2021
30
Effects of miR-599 targeting YAP1 on proliferation, invasion and apoptosis of bladder urothelial carcinoma cells. 61
33359177 2021
31
Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery. 61
33589927 2021
32
CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers. 61
33576304 2021
33
Prognostic and immunological role of Fam20C in pan-cancer. 61
33306121 2021
34
Histological Characterization of Feline Bladder Urothelial Carcinoma. 61
33494910 2021
35
Shear Wave Elasticity Differentiation Between Low- and High-Grade Bladder Urothelial Carcinoma and Correlation With Collagen Fiber Content. 61
32644243 2021
36
FUT7 Promotes the Epithelial-Mesenchymal Transition and Immune Infiltration in Bladder Urothelial Carcinoma. 61
33790621 2021
37
Use of psychotropic drugs among older patients with bladder cancer in the United States. 61
33507622 2021
38
Cannabis-Derived Compounds Cannabichromene and Δ9-Tetrahydrocannabinol Interact and Exhibit Cytotoxic Activity against Urothelial Cell Carcinoma Correlated with Inhibition of Cell Migration and Cytoskeleton Organization. 61
33477303 2021
39
ABT-751 Induces Multiple Anticancer Effects in Urinary Bladder Urothelial Carcinoma-Derived Cells: Highlighting the Induction of Cytostasis through the Inhibition of SKP2 at Both Transcriptional and Post-Translational Levels. 61
33478005 2021
40
Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma. 61
33435173 2021
41
Emerging role of RNF2 in cancer: From bench to bedside. 61
33400276 2021
42
The pancancer landscape of Wnt family expression reveals potential biomarkers in urinary system tumors. 61
33311568 2020
43
The panoramic picture of pepsinogen gene family with pan-cancer. 61
33067881 2020
44
Evaluation of miR-130 family members as circulating biomarkers for the diagnosis of bladder cancer. 61
32761678 2020
45
Many Different LINE-1 Retroelements Are Activated in Bladder Cancer. 61
33322422 2020
46
Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. 61
33386276 2020
47
Survival nomogram for patients with upper tract recurrence after resection for localized bladder urothelial carcinoma. 61
32892645 2020
48
Establishment of diagnostic criteria for upper urinary tract urothelial carcinoma based on genome-wide DNA methylation analysis. 61
32498593 2020
49
A novel prognostic biomarker for muscle invasive bladder urothelial carcinoma based on 11 DNA methylation signature. 61
33151129 2020
50
MAFG-AS1 promotes tumor progression via regulation of the HuR/PTBP1 axis in bladder urothelial carcinoma. 61
33377647 2020
Sources

Variations for Bladder Urothelial Carcinoma

About this section

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

6 (show top 50) (show all 276)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MTOR NM_004958.4(MTOR):c.6040G>A (p.Glu2014Lys) SNV Likely pathogenic 376131 rs1057519780 GRCh37: 1:11187857-11187857
GRCh38: 1:11127800-11127800
2 MTOR NM_004958.4(MTOR):c.7255G>A (p.Glu2419Lys) SNV Likely pathogenic 156709 rs587777900 GRCh37: 1:11174420-11174420
GRCh38: 1:11114363-11114363
3 ERBB2 NM_004448.3(ERBB2):c.2033G>A (p.Arg678Gln) SNV Likely pathogenic 376344 rs1057519862 GRCh37: 17:37879658-37879658
GRCh38: 17:39723405-39723405
4 CNOT9 NM_005444.3(CNOT9):c.259T>C (p.Ser87Pro) SNV Likely pathogenic 376526 rs1057519956 GRCh37: 2:219447748-219447748
GRCh38: 2:218583025-218583025
5 ERBB3 NM_001982.3(ERBB3):c.889G>T (p.Asp297Tyr) SNV Likely pathogenic 376407 rs1057519891 GRCh37: 12:56482341-56482341
GRCh38: 12:56088557-56088557
6 CNOT9 NM_005444.3(CNOT9):c.260C>G (p.Ser87Cys) SNV Likely pathogenic 376527 rs1057519957 GRCh37: 2:219447749-219447749
GRCh38: 2:218583026-218583026
7 ERBB3 NM_001982.3(ERBB3):c.890A>T (p.Asp297Val) SNV Likely pathogenic 376408 rs1057519892 GRCh37: 12:56482342-56482342
GRCh38: 12:56088558-56088558
8 ERBB2 NM_004448.3(ERBB2):c.2264T>C (p.Leu755Ser) SNV Likely pathogenic 376035 rs121913470 GRCh37: 17:37880220-37880220
GRCh38: 17:39723967-39723967
9 ERBB2 NM_004448.3(ERBB2):c.2264T>G (p.Leu755Trp) SNV Likely pathogenic 376343 rs121913470 GRCh37: 17:37880220-37880220
GRCh38: 17:39723967-39723967
10 ERBB3 NM_001982.3(ERBB3):c.889G>A (p.Asp297Asn) SNV Likely pathogenic 376409 rs1057519891 GRCh37: 12:56482341-56482341
GRCh38: 12:56088557-56088557
11 ERBB2 NM_004448.3(ERBB2):c.2263T>A (p.Leu755Met) SNV Likely pathogenic 376404 rs1057519890 GRCh37: 17:37880219-37880219
GRCh38: 17:39723966-39723966
12 ERBB3 NM_001005915.1(ERBB3):c.310G>T (p.Val104Leu) SNV Likely pathogenic 376411 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
13 ERBB3 NM_001005915.1(ERBB3):c.310G>A (p.Val104Met) SNV Likely pathogenic 376410 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
14 RHEB NM_005614.4(RHEB):c.103T>A (p.Tyr35Asn) SNV Likely pathogenic 376515 rs1057519949 GRCh37: 7:151188050-151188050
GRCh38: 7:151490964-151490964
15 RHEB NM_005614.4(RHEB):c.104A>G (p.Tyr35Cys) SNV Likely pathogenic 376516 rs1057519950 GRCh37: 7:151188049-151188049
GRCh38: 7:151490963-151490963
16 HRAS , LRRC56 NM_005343.4(HRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 376322 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
17 U2AF1 NM_001025203.1(U2AF1):c.101C>T (p.Ser34Phe) SNV Likely pathogenic 376025 rs371769427 GRCh37: 21:44524456-44524456
GRCh38: 21:43104346-43104346
18 TP53 NM_000546.5(TP53):c.526T>G (p.Cys176Gly) SNV Likely pathogenic 376571 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
19 TP53 NM_000546.5(TP53):c.797G>T (p.Gly266Val) SNV Likely pathogenic 233303 rs193920774 GRCh37: 17:7577141-7577141
GRCh38: 17:7673823-7673823
20 CREBBP NM_004380.3(CREBBP):c.4337G>T (p.Arg1446Leu) SNV Likely pathogenic 376386 rs1057519884 GRCh37: 16:3788617-3788617
GRCh38: 16:3738616-3738616
21 SF3B1 NM_012433.3(SF3B1):c.1874G>A (p.Arg625His) SNV Likely pathogenic 376534 rs1057519961 GRCh37: 2:198267483-198267483
GRCh38: 2:197402759-197402759
22 ERBB2 NM_004448.3(ERBB2):c.2305G>T (p.Asp769Tyr) SNV Likely pathogenic 375992 rs121913468 GRCh37: 17:37880261-37880261
GRCh38: 17:39724008-39724008
23 CDKN2A NM_000077.4(CDKN2A):c.248A>G (p.His83Arg) SNV Likely pathogenic 376379 rs1057519881 GRCh37: 9:21971110-21971110
GRCh38: 9:21971111-21971111
24 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu) SNV Likely pathogenic 230253 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
25 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely pathogenic 13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
26 FBXW7 NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser) SNV Likely pathogenic 376426 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
27 TP53 NM_000546.5(TP53):c.527G>A (p.Cys176Tyr) SNV Likely pathogenic 186451 rs786202962 GRCh37: 17:7578403-7578403
GRCh38: 17:7675085-7675085
28 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His) SNV Likely pathogenic 156444 rs121913500 GRCh37: 2:209113112-209113112
GRCh38: 2:208248388-208248388
29 TP53 NM_001276697.2(TP53):c.-26C>G SNV Likely pathogenic 376640 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
30 NRAS NM_002524.5(NRAS):c.37G>C (p.Gly13Arg) SNV Likely pathogenic 13899 rs121434595 GRCh37: 1:115258745-115258745
GRCh38: 1:114716124-114716124
31 RXRA NM_002957.6(RXRA):c.1280C>T (p.Ser427Phe) SNV Likely pathogenic 376528 rs1057519958 GRCh37: 9:137328351-137328351
GRCh38: 9:134436505-134436505
32 TP53 NM_000546.5(TP53):c.843C>G (p.Asp281Glu) SNV Likely pathogenic 376587 rs1057519984 GRCh37: 17:7577095-7577095
GRCh38: 17:7673777-7673777
33 CTNNB1 NM_001904.4(CTNNB1):c.97T>G (p.Ser33Ala) SNV Likely pathogenic 376392 rs1057519886 GRCh37: 3:41266100-41266100
GRCh38: 3:41224609-41224609
34 SF3B1 NM_012433.3(SF3B1):c.1873C>T (p.Arg625Cys) SNV Likely pathogenic 376535 rs775623976 GRCh37: 2:198267484-198267484
GRCh38: 2:197402760-197402760
35 CREBBP NM_004380.3(CREBBP):c.4337G>A (p.Arg1446His) SNV Likely pathogenic 376387 rs1057519884 GRCh37: 16:3788617-3788617
GRCh38: 16:3738616-3738616
36 TP53 NM_000546.5(TP53):c.733G>C (p.Gly245Arg) SNV Likely pathogenic 376604 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
37 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely pathogenic 376473 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
38 NFE2L2 NM_006164.5(NFE2L2):c.235G>C (p.Glu79Gln) SNV Likely pathogenic 376465 rs1057519922 GRCh37: 2:178098810-178098810
GRCh38: 2:177234082-177234082
39 TP53 NM_000546.5(TP53):c.523C>G (p.Arg175Gly) SNV Likely pathogenic 376649 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
40 NRAS NM_002524.5(NRAS):c.38G>A (p.Gly13Asp) SNV Likely pathogenic 13901 rs121434596 GRCh37: 1:115258744-115258744
GRCh38: 1:114716123-114716123
41 TP53 NM_000546.5(TP53):c.815T>G (p.Val272Gly) SNV Likely pathogenic 233323 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
42 TP53 NM_000546.5(TP53):c.839G>T (p.Arg280Ile) SNV Likely pathogenic 161517 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
43 CDKN2A NM_000077.4(CDKN2A):c.239G>A (p.Arg80Gln) SNV Likely pathogenic 376385 rs1057519883 GRCh37: 9:21971119-21971119
GRCh38: 9:21971120-21971120
44 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr) SNV Likely pathogenic 376585 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
45 NFE2L2 NM_006164.5(NFE2L2):c.86A>G (p.Asp29Gly) SNV Likely pathogenic 376464 rs1057519921 GRCh37: 2:178098959-178098959
GRCh38: 2:177234231-177234231
46 CTNNB1 NM_001904.4(CTNNB1):c.95A>C (p.Asp32Ala) SNV Likely pathogenic 376229 rs121913396 GRCh37: 3:41266098-41266098
GRCh38: 3:41224607-41224607
47 HRAS , LRRC56 NM_005343.4(HRAS):c.183G>T (p.Gln61His) SNV Likely pathogenic 376318 rs121913496 GRCh37: 11:533873-533873
GRCh38: 11:533873-533873
48 TP53 NM_000546.5(TP53):c.577C>A (p.His193Asn) SNV Likely pathogenic 376614 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
49 PIK3CA NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu) SNV Likely pathogenic 13654 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
50 FBXW7 NM_001349798.2(FBXW7):c.1436G>A (p.Arg479Gln) SNV Likely pathogenic 376419 rs866987936 GRCh37: 4:153247366-153247366
GRCh38: 4:152326214-152326214
Sources

Expression for Bladder Urothelial Carcinoma

About this section
Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.
Sources

Pathways for Bladder Urothelial Carcinoma

About this section

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.14 TP53 PTEN PIK3CA MTOR KRAS IDH1
2
ERK Signaling 63
Show member pathways
 13.95 TP53 PTEN MTOR KRAS HRAS FGFR3
3
HIV Life Cycle 65
Show member pathways
 13.83 PIK3CA MTOR KRAS IDH1 HRAS FGFR3
4
TGF-Beta Pathway 63
Show member pathways
 13.65 TP53 PIK3CA MTOR KRAS HRAS FGFR3
5
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.58 TP53 PTEN PIK3CA MTOR KRAS HRAS
6
Akt Signaling 63
Show member pathways
 13.54 TP53 PTEN MTOR KRAS HRAS FGFR3
7
Cytokine Signaling in Immune system 65
Show member pathways
 13.46 TP53 PIK3CA KRAS HRAS FGFR3 ERBB2
8
PAK Pathway 63
Show member pathways
 13.41 PTEN KRAS HRAS FGFR3 ERBB2 CTNNB1
9
PI3K/AKT activation 65
Show member pathways
 13.24 TP53 PTEN PIK3CA MTOR FGFR3 ERBB2
10
TNFR1 Pathway 63
Show member pathways
 13.21 TP53 PTEN PIK3CA MTOR KRAS HRAS
11
Phospholipase-C Pathway 63
Show member pathways
 13.2 TP53 PTEN MTOR KRAS HRAS FGFR3
12
PI3K-Akt signaling pathway 36
Show member pathways
 13.15 TP53 PTEN PIK3CA MTOR KRAS HRAS
13
Human cytomegalovirus infection 36
Show member pathways
 13.09 TP53 PIK3CA MTOR KRAS HRAS CTNNB1
14
Focal Adhesion 36 1
Show member pathways
 13.04 PTEN PIK3CA KRAS HRAS ERBB2 CTNNB1
15
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.03 PTEN PIK3CA MTOR KRAS HRAS FGFR3
16
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 12.99 PTEN PIK3CA MTOR KRAS HRAS AKT1
17
ErbB4 Pathway 63
Show member pathways
 12.96 TP53 PTEN MTOR KRAS HRAS ERBB2
18
Endometrial cancer 36
Show member pathways
 12.93 TP53 PTEN PIK3CA MTOR KRAS HRAS
19
Beta-Adrenergic Signaling 63
Show member pathways
 12.91 MTOR KRAS HRAS CTNNB1 AKT1
20
IL-9 Signaling Pathways 64
Show member pathways
 12.91 PTEN PIK3CA MTOR KRAS HRAS AKT1
21
MAPK signaling pathway 36 1
12.9 TP53 KRAS HRAS FGFR3 ERBB2 AKT1
22
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.9 TP53 PTEN PIK3CA MTOR KRAS HRAS
23
Development HGF signaling pathway 23
Show member pathways
 12.88 TP53 PTEN PIK3CA MTOR KRAS HRAS
24
Ras signaling pathway 36
Show member pathways
 12.87 PIK3CA KRAS HRAS FGFR3 CTNNB1 AKT1
25
Gastric cancer 36
Show member pathways
 12.86 TP53 PTEN PIK3CA MTOR KRAS HRAS
26
Apoptosis Modulation and Signaling 1
Show member pathways
 12.85 TP53 PIK3CA KRAS HRAS CDKN2A AKT1
27
Glioma 36
Show member pathways
 12.84 TP53 PTEN PIK3CA MTOR KRAS HRAS
28
RANK Signaling in Osteoclasts 63
Show member pathways
 12.77 PIK3CA MTOR KRAS HRAS AKT1
29
Immune response IL-23 signaling pathway 23
Show member pathways
 12.76 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
30
T cell receptor signaling pathway 36
Show member pathways
 12.75 PTEN PIK3CA MTOR KRAS HRAS AKT1
31
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.72 PTEN PIK3CA KRAS HRAS AKT1
32
Pathways in cancer 36
12.72 TP53 PTEN PIK3CA MTOR KRAS HRAS
33
Angiopoietin Like Protein 8 Regulatory Pathway 1
Show member pathways
 12.66 PTEN PIK3CA MTOR HRAS AKT1
34
MicroRNAs in cancer 36
12.65 TP53 PTEN PIK3CA MTOR KRAS HRAS
35
Prolactin Signaling Pathway 1 36
Show member pathways
 12.64 PTEN PIK3CA MTOR KRAS HRAS ERBB2
36
MET promotes cell motility 65
Show member pathways
 12.63 PIK3CA MTOR KRAS HRAS AKT1
37
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.63 TP53 PIK3CA MTOR HRAS AKT1
38
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.61 PTEN PIK3CA MTOR KRAS HRAS AKT1
39
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.6 TP53 PTEN PIK3CA MTOR KRAS HRAS
40
ErbB signaling pathway 36 1
Show member pathways
 12.57 TP53 PTEN PIK3CA MTOR KRAS HRAS
41
Development IGF-1 receptor signaling 23
Show member pathways
 12.56 TP53 PTEN PIK3CA MTOR HRAS AKT1
42
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.55 PTEN PIK3CA KRAS HRAS AKT1
43
Shigellosis 36
12.55 U2AF1 TP53 PIK3CA MTOR AKT1
44
Phospholipase D signaling pathway 36
Show member pathways
 12.55 PIK3CA MTOR KRAS HRAS AKT1
45
Development FGFR signaling pathway 23
Show member pathways
 12.55 PIK3CA KRAS HRAS FGFR3 AKT1
46
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.55 PIK3CA MTOR KRAS HRAS FGFR3 ERBB2
47
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.54 PIK3CA KRAS HRAS CTNNB1 AKT1
48
VEGF Signaling 66
Show member pathways
 12.52 TP53 PTEN MTOR KRAS HRAS FGFR3
49
mTOR signalling 65
Show member pathways
 12.51 PIK3CA MTOR FGFR3 AKT1
50
JAK-STAT signaling pathway 36
Show member pathways
 12.51 PIK3CA MTOR HRAS AKT1
Sources

GO Terms for Bladder Urothelial Carcinoma

About this section

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10.07 PIK3CA MTOR FGFR3 ERBB2 CDKN2A AKT1
2 apoptotic process GO:0006915 10.06 TP53 PTEN HRAS FGFR3 CDKN2A AKT1
3 negative regulation of cell proliferation GO:0008285 10.02 TP53 PTEN HRAS CTNNB1 CDKN2A
4 positive regulation of apoptotic process GO:0043065 9.97 TP53 PTEN CTNNB1 CDKN2A AKT1
5 heart development GO:0007507 9.93 TP53 PTEN ERBB2 CTNNB1
6 positive regulation of cell proliferation GO:0008284 9.91 PTEN KRAS HRAS FGFR3 ERBB2 CTNNB1
7 positive regulation of protein kinase B signaling GO:0051897 9.9 PIK3CA MTOR FGFR3 ERBB2
8 protein autophosphorylation GO:0046777 9.88 MTOR FGFR3 ERBB2 AKT1
9 positive regulation of protein phosphorylation GO:0001934 9.85 MTOR KRAS HRAS ERBB2 AKT1
10 cell cycle arrest GO:0007050 9.83 TP53 MTOR HRAS CDKN2A
11 positive regulation of MAPK cascade GO:0043410 9.81 HRAS FGFR3 ERBB2 CTNNB1
12 cellular response to growth factor stimulus GO:0071363 9.79 ERBB2 CTNNB1 AKT1
13 positive regulation of MAP kinase activity GO:0043406 9.78 KRAS HRAS ERBB2
14 Ras protein signal transduction GO:0007265 9.73 TP53 KRAS HRAS CDKN2A
15 protein kinase B signaling GO:0043491 9.71 PTEN PIK3CA AKT1
16 cell aging GO:0007569 9.67 TP53 MTOR HRAS
17 regulation of myelination GO:0031641 9.65 MTOR CTNNB1 AKT1
18 response to isolation stress GO:0035900 9.61 KRAS HRAS
19 negative regulation of macroautophagy GO:0016242 9.58 PIK3CA MTOR AKT1
20 negative regulation of immature T cell proliferation in thymus GO:0033088 9.56 ERBB2 CDKN2A
21 cellular response to decreased oxygen levels GO:0036294 9.55 PTEN AKT1
22 cellular response to hypoxia GO:0071456 9.55 TP53 PTEN MTOR MALAT1 AKT1
23 anoikis GO:0043276 9.5 PIK3CA MTOR AKT1
24 negative regulation of cell size GO:0045792 9.43 PTEN MTOR AKT1
25 positive regulation of gene expression GO:0010628 9.28 TP53 PTEN MTOR KRAS HRAS ERBB2
26 phosphatidylinositol 3-kinase signaling GO:0014065 9.26 PTEN PIK3CA ERBB2 AKT1

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.86 TP53 PTEN MTOR KRAS IDH1 FGFR3
2 kinase activity GO:0016301 9.63 PIK3CA MTOR FGFR3 ERBB2 CDKN2A AKT1
3 MDM2/MDM4 family protein binding GO:0097371 9.32 TP53 CDKN2A
4 disordered domain specific binding GO:0097718 9.13 TP53 CTNNB1 CDKN2A
5 protein kinase binding GO:0019901 9.1 TP53 PTEN MTOR CTNNB1 CDKN2A AKT1
Sources

Sources for Bladder Urothelial Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....